BLASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
6/8 — Strong
Priority Review
TEZSPIRE (tezepelumab-ekko) by AstraZeneca is thymic stromal lymphopoietin blockers [moa]. Approved for thymic stromal lymphopoietin blocker [epc]. First approved in 2021.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEZSPIRE (tezepelumab-ekko) is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key driver of type 2 inflammation. It is approved for asthma and addresses a novel mechanistic pathway upstream of traditional IL-4/IL-13 inhibitors. The drug targets patients with moderate-to-severe asthma, including those with type 2-high phenotypes.
$88MPart D
PeakThe product is in peak commercial phase with moderate spending signals; expect stable to growing field teams supporting specialty distribution.
Mechanism of Action
Thymic Stromal Lymphopoietin Blockers
Pharmacologic Class:
Thymic Stromal Lymphopoietin Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
Started Nov 2026
210 enrolled
Severe AsthmaChronic Rhinosinusitis With Nasal Polyps(CRSwNP)
Tezepelumab CRSwNP Real World Study (CREW Study)
Started Oct 2026
100 enrolled
Chronic Rhinosinusitis With Nasal Polyps
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
Started Jun 2026
200 enrolled
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
Started Apr 2026
230 enrolled
Chronic Rhinosinusitis With Nasal Polyps
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Started Jan 2026
400 enrolled
Severe Asthma
Worked on TEZSPIRE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.